ZILRETTA

Pacira Pharmaceuticals, Inc. has initiated a Class II recall for 40,517 kits of Zilretta (triamcinolone acetonide extended-release injectable suspension) due to failed dissolution specifications. This voluntary, firm-initiated action impacts US nationwide distribution, necessitating immediate review of inventory and potential supply chain adjustments for buyers of intra-articular corticosteroids.

Pacira Pharmaceuticals, Inc. has initiated a Class II nationwide recall of 43,768 kits of ZILRETTA (triamcinolone acetonide extended-release injectable suspension). This action, triggered by failed stability specifications, mandates immediate attention from procurement directors and supply chain VPs to mitigate disruption and assess the implications for product quality and patient access across the U.S.